tiprankstipranks
Medigene AG (GB:0QGJ)
LSE:0QGJ
Holding GB:0QGJ?
Track your performance easily

Medigene (0QGJ) Income Statement

1 Followers

Medigene Income Statement

Last quarter (Q2 2022), Medigene's total revenue was €2.26M, an increase of 74.33% from the same quarter last year. In Q2, Medigene's net income was €-2.39M. See Medigene’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
€ 10.27M€ 31.25M€ 10.46M€ 8.00M€ 66.27M€ 86.89M
Cost of Revenue
€ 904.00K€ 1.98M€ 1.36M€ 1.29M--
Gross Profit
€ 9.37M€ 29.26M€ 9.10M€ 6.71M--
Operating Expense
€ 23.90M€ 37.99M€ 19.09M€ 30.04M--
Operating Income
€ -14.53M€ -8.73M€ -9.98M€ -23.33M--
Net Non Operating Interest Income Expense
€ -344.00K€ -630.00K€ -283.00K€ 211.00K--
Other Income Expense
------
Pretax Income
€ -10.21M€ -9.37M€ -10.28M€ -28.40M€ 34.82M€ 30.73M
Tax Provision
€ 494.00K€ -1.04M€ -300.00K€ 472.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
€ -10.71M€ -8.33M€ -9.98M€ -28.88M€ 34.82M€ 30.73M
Basic EPS
€ -0.44€ -0.34€ -0.41€ -1.18--
Diluted EPS
€ -0.44€ -0.34€ -0.41€ -1.18--
Basic Average Shares
€ 98.25M€ 24.56M€ 24.56M€ 24.56M--
Diluted Average Shares
€ 98.25M€ 24.56M€ 24.56M€ 24.56M--
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-€ 163.00K€ 104.00K€ 114.00K--
Total Expenses
€ 24.80M€ 39.97M€ 20.45M€ 31.34M--
Net Income From Continuing And Discontinued Operation
€ -10.71M€ -8.33M€ -9.98M€ -28.88M€ 34.82M€ 30.73M
Normalized Income
€ -13.98M€ -8.33M€ -9.98M€ -28.88M--
Interest Expense
€ 400.00K€ 659.00K€ 364.00K€ 428.00K€ 14.69M€ 18.36M
EBIT
€ -9.81M€ -8.71M€ -9.92M€ -27.98M--
EBITDA
€ -9.81M€ 13.14M€ -6.49M€ -21.50M--
Currency in EUR

Medigene Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis